deltatrials
Completed PHASE3 NCT00980005

Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children

Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children

Sponsor: GlaxoSmithKline

Conditions Influenza
Interventions Fluzone® GSK investigational vaccine GSK1557482A
Updated 8 times since 2017 Last updated: Aug 22, 2018 Started: Oct 13, 2009 Primary completion: Mar 2, 2010 Completion: Jun 17, 2010

A PHASE3 clinical study on Influenza, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 8 data snapshots since 2009. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Oct 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. Jun 2018 — Oct 2018 [monthly]

    Completed PHASE3

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Oct 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States, Austin, United States, Austintown, United States, Benton, United States, Birmingham, United States, Burke, United States, Cary, United States, Charleston, United States, Cortland, United States, DeKalb, United States and 18 more location s